Curis Board Approves 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing
CRIS has more than doubled off its 52-week low of $0.181 on elevated volume (4.1× avg).
Summary
Curis Inc.'s Board of Directors has approved a 1-for-20 reverse stock split, finalizing the ratio to address the company's Nasdaq delisting threat.
Key Events · Corporate Governance and Compliance · CRIS
-
Reverse Stock Split Approved
The Board of Directors approved a 1-for-20 reverse stock split, effective June 25, 2026, following shareholder authorization.
-
Nasdaq Delisting Compliance
This action is a direct response to the company's delisting notice from Nasdaq, aiming to meet the minimum bid price requirement.
-
Finalizes Board Discretion
The Board's decision sets the specific 1-for-20 ratio, which was previously approved by shareholders as a range between 1-for-5 and 1-for-25.
Analysis · CRIS · Life Sciences
This filing confirms the Board's decision to implement a 1-for-20 reverse stock split, a critical step to regain compliance with Nasdaq's minimum bid price requirement. The company has been facing a delisting notice and previously disclosed "going concern" doubts, making this action essential for its continued listing on a major exchange. While reverse splits are often viewed negatively as they do not address underlying business issues, this move is necessary to avoid delisting, which would severely impact liquidity and investor confidence.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 39.9% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRIS was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.4M. The 52-week trading range was $0.18 to $2.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.